The authors would like to acknowledge Dr. Su, PhD, for her statistical analysis of the data. The authors also thank Dr. McClure, DVM, PhD DACLAM, for her advice on the anesthesia and pain management protocols used in the study. This project was supported by grants from Western University of Health Sciences Office of the Vice President for Research (12678v) and USDA Section 1433 funds (2090).

All methods described here have been approved by the Institutional Animal Care and Use Committee (IACUC) of Western University of Health Sciences.
1. Isolation and Expansion of MSCs from Equine Umbilical Cord Matrix
<ol>
	<li>Obtain the placenta from an adult mare (pregnant) after observed foaling and aseptically isolate the umbilical cord from the placenta. Keep the umbilical cord in phosphate buffered saline (PBS) with 1% penicillin-streptomycin (P/S) at 4 &#176;C during transfer until processing.</li>
	<li>Wash the umbilical cord twice with room temperature PBS with 1% P/S in a 50 mL tube. Section the umbilical cord into 2-inch-long fragments on 150 mm plate and wash in room temperature PBS with 1% P/S in a 50 mL tube two or three times, until most of the blood is rinsed out.</li>
	<li>Cut the umbilical cord longitudinally to expose vessels. Remove vessels, including 2 arteries, a vein, and an allantoic stalk from the cord using forceps and scissors. Collect umbilical cord matrix (Wharton&#39;s Jelly), which is the jelly-like matrix surrounding vessels, onto a 150 mm plate by scraping with a scalpel, and mince the jelly into fine pieces.</li>
	<li>Place Wharton&#39;s Jelly from 2&#8211;3 umbilical cord fragments (approximately 12&#8211;15 g) in a 50-mL tube with 15 mL of 0.1% (w/v) collagenase type IA solution in PBS. Incubate at 37 &#176;C with gentle shaking for 3-4 h until dissolved.</li>
	<li>Centrifuge digested tissue at 300 x g for 15 min and aspirate supernatant. Resuspend digested tissue in 15 mL of room temperature PBS with 1% P/S, mix by pipetting, centrifuge at 150 x g for 5 min, and aspirate supernatant (wash). Repeat washing twice more.</li>
	<li>Resuspend washed cells in 15 mL of room temperature PBS with 1% P/S, mix by pipetting, strain by with 100 &#181;m cell strainer, centrifuge at 150 x g for 5 min, and aspirate supernatant.</li>
	<li>Prepare culture medium (CM) by mixing low glucose Dulbecco&#39;s Modified Eagle&#39;s Medium (LG-DMEM) with fetal bovine serum (FBS) and 1% P/S. Sterilize the medium by filtration.</li>
	<li>Resuspend strained cells in 10 mL of CM pre-warmed to 37 &#176;C, mix by pipetting, transfer into a 25 cm2 tissue culture flask, and incubate in 5% CO2 at 90% humidity and 37.0 &#176;C. Change CM every 3 days until the culture reaches 70&#8211;80% confluence, when the culture will be passaged.</li>
	<li>To passage the culture, aspirate CM from flask, wash with 5 mL of room temperature PBS twice, and detach with 3 mL of 0.25% trypsin/ethylenediaminetetraacetic acid (EDTA) at 37 &#176;C for 5 min.</li>
	<li>Neutralize trypsin/EDTA with 6 mL of CM pre-warmed to 37.0 &#176;C, mix by pipetting, transfer into a 15 mL tube, centrifuge at 150 x g for 5 min, and aspirate supernatant. Resuspend detached cells in 1 mL of CM, mix by pipetting. Count the viable cells using trypan blue and hemocytometer. Re-seed into a 25 cm2 tissue culture flask at 5,000 cells/cm2, and incubate in 5% CO2 at 90% humidity and 37.0 &#176;C.</li>
</ol>
2. Preparation of Spheroids with UCM-MSCs Cultured on Chitosan Films
<ol>
	<li>To prepare 100 mL of 1% (w/v) chitosan solution, add 1 g of chitosan in 99 mL of distilled water (dH2O), and mix well with a magnetic stirrer.</li>
	<li>Add 670 &#181;L of glacial acetic acid and continue mixing until chitosan dissolves and becomes viscous. This usually takes 3&#8211;4 h.</li>
	<li>Add 500 &#181;L of chitosan solution into each well of the 12-well tissue culture plate, and swirl the plate to distribute chitosan solution evenly and cover all of the bottom surface.</li>
	<li>Dry the chitosan solution coated plate under laminar flow cabinet without a cover overnight for 24 h. Once dried, thin film will be formed and adhered to plate.</li>
	<li>Neutralize chitosan film by adding 1 mL of 0.5 N sodium hydroxide (NaOH) solution into each well and incubate for 2 h at room temperature. Aspirate NaOH from each well and wash each well with 1 mL of dH2O three times. Wash each well with 1 mL of 70% ethanol (EtOH) once.</li>
	<li>To sterilize chitosan film, add 1 mL of 70% EtOH into each well and incubate overnight in laminar flow cabinet. Aspirate remaining EtOH from each well in the following day. Wash each well with 1 mL of sterile PBS three times. Sterilize chitosan film with ultraviolet light under laminar flow cabinet overnight without a cover.</li>
	<li>To form spheroids of UCM-MSCs, seed expanded and passaged cells into each well at 5,000 cells/cm2, and incubate in 5% CO2 at 90% humidity and 37.0 &#176;C. 
	NOTE: Cells can be incubated under hypoxia or normoxia, depending on the investigator&#39;s interest.</li>
</ol>
3. Expression of Surface Markers Analyzed via Flow Cytometry
<ol>
	<li>Preparation of a single cell suspension
	<ol>
		<li>Standard plate
		<ol>
			<li>Remove medium from each well and wash twice with room temperature PBS.</li>
			<li>Detach cells with 500 &#181;L of a cell dissociation reagent into each well of a 12-well plate for 5&#8211;10 min at room temperature.</li>
			<li>After incubation, add 1 ml of staining buffer (PBS containing 0.5% BSA) into each well and mix by pipetting to detach cells.</li>
			<li>Transfer cell suspension into 15 mL conical tube and centrifuge at 150 x g for 5 min.</li>
		</ol>
		</li>
		<li>Chitosan plate
		<ol>
			<li>Collect all spheroids by aspirating medium using a pipette with a 1,000 &#181;L tip. Transfer collected medium into a 15-mL conical tube. After collecting medium, wash well by adding 1 mL of PBS, and transfer washed PBS into the same 15 mL conical tube.</li>
			<li>Centrifuge spheroids at 150 x g for 5 min and remove supernatant.</li>
			<li>Add 500 &#181;L of the cell dissociation reagent (e.g., accutase) and incubate for 5&#8211;10 min at room temperature. Mix by pipetting using a 1 mL tip until spheroids dissociate and are no longer visible.</li>
			<li>Add 1 mL of staining buffer into the single cell suspension and centrifuge at 150 x g for 5 min.</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Washing cells
	<ol>
		<li>Remove the supernatant from the conical tube and re-suspend the cells in 3 mL of cold staining buffer. Keep cells on ice throughout experiment from this step.</li>
		<li>Centrifuge at 300 x g for 5 min (washing).</li>
		<li>Wash twice.</li>
	</ol>
	</li>
	<li>Staining cells
	<ol>
		<li>Centrifuge at 300 x g for 5 min and remove supernatant.</li>
		<li>Count viable cells using a trypan blue and hemocytometer. Re-suspend 1 x 106 cells in 50 &#181;L blocking buffer (PBS containing 10% horse serum) and incubate for 30 min on ice.</li>
		<li>Add 10 &#181;L fluorescein isothiocyanate (FITC) conjugated antibodies (CD44, CD90, CD105, CD34, major histocompatibility complex (MHC) class II, or isotype control for each antibody) and 40 &#181;L of staining buffer, then incubate protected from light for 1 h on ice.</li>
		<li>Add 3 mL of cold staining buffer and mix, centrifuge at 300 x g for 5 min, and aspirate supernatant (washing).</li>
		<li>Repeat washing twice.</li>
		<li>Re-suspend the cell pellet in 0.5 mL of staining buffer</li>
		<li>Add 5 &#181;L of 7-AAD (viability dye) and incubate for 30 min on ice</li>
		<li>Analyze stained cell samples by flow cytometer. Exclude debris by their smaller SSC and FSC, and identify viable cells with lower uptake of 7-AAD. Plot FL1 and FL2 on the y- and x- axes, respectively. Use isotype control to create a gate above the diagonal line. Measure the percentage of positively stained cells in the area. Count at least 20,000 events/sample (Supplementary Figure 1).</li>
		<li>Measure the percentage of cells stained with antibodies by gating viable cells and auto-fluorescence, and subtract percentage of cells stained with isotype control.</li>
	</ol>
	</li>
</ol>
4. Bilateral Patellar Tendon Defect Model in the Rat
<ol>
	<li>Select Sprague-Dawley rats (adult male, 4&#8211;5 months old, body weight 350&#8211;375 g). Note the relatively large size of the rats used for this model.</li>
	<li>Anesthetize&#160;and apply artificial eye lubricant the rat with 8% sevoflurane in 2 L/min 100% oxygen delivered via mask, until disappearance of pinch-toe reflex in the induction chamber.</li>
	<li>Administer an intramuscular injection of Meloxicam (1 mg/kg) as preemptive analgesia.</li>
	<li>Place the rat between two 0.5 L water bottles filled with warm water and covered with a cloth to maintain body temperature and position, while preventing skin injury. Tape each extremity to the table. To reduce risk of hypothermia, cover the body with bubble wrap (Figure 1).</li>
	<li>Maintain anesthesia with continuous flow of 5% sevoflurane in 1 L 100% oxygen mixture via nose cone, with the animal on dorsal recumbency on water heating pad.</li>
	<li>To avoid skin trauma, do not clip the surgical sites. Instead, apply hair remover cream over both stifles. Use a tongue depressor to remove the cream and hair.</li>
	<li>Scrub the surgical site with chlorhexidine digluconate scrub, and rinse with 70% ethanol 3 times.</li>
	<li>Incise the skin with a sterile #15 scalpel blade in a proximal to distal direction, on the craniomedial aspect of the stifle. Start the incision about 1 cm proximal to the level of the patella, and extend it approximately 5 mm distal to the tibial tubercle.</li>
	<li>Reflect the skin to expose the patellar tendon by freeing the underlying subcutaneous tissue with a #15 scalpel blade.</li>
	<li>Using the #15 scalpel blade, excise the central third of each patellar tendon (1 mm) from the distal aspect of the patella to the tibial tuberosity.
	<ol>
		<li>Align a 0.99 mm-diameter Kirschner wire against the tendon as a template to standardize the size of the defect in each limb (Figure 2).</li>
		<li>Make 2 full-thickness incisions on each side of the Kirschner wire with a #15 scalpel blade to isolate the central portion of the tendon (Figure 3). Resect the central section proximally and distally with fine Iris scissors (Figure 4).</li>
		<li>Before closing the fascia of the stifle, insert the clot (mixed cell suspension and ACP) for the appropriate treatment groups as described in 5.5. Close the fascia with a cruciate pattern and skin with an intradermal pattern using 5-0 polyglactin 910 sutures (Figure 5).</li>
	</ol>
	</li>
	<li>Repeat the procedure on the contralateral stifle. 
	NOTE: One defect is randomly assigned to a treatment (stem cells conditioned on chitosan or cultured on standard plates). The contralateral defect is left empty, to serve as internal control.</li>
	<li>After surgery, administer 4 tablets of enrofloxacin (2 mg/tablet, orally, once daily) and a tablet of meloxicam (2 mg/tablet, orally, once daily) for 7 days.&#160;These doses were recommended by a laboratory animal veterinarian and approved in the IACUC protocol.</li>
</ol>
5. Delivery of MSCs within the Patellar Tendon Defect
<ol>
	<li>Anesthetize a healthy rat which is not used for patellar tendon defect creation with 8% sevoflurane in 2 L/min 100 % oxygen delivered via mask, until disappearance of pinch-toe reflex in the induction chamber.</li>
	<li>Collect 5 mL blood by cardiac puncture from the anesthetized Sprague-Dawley rat (adult male, 4&#8211;5 months old, body weight 350&#8211;375 g), in a 5 mL syringe with a 20 G needle containing 1 mL of acid-citrate-dextrose (5:1 v/v).</li>
	<li>Euthanize the rat after cardiac puncture and blood collection, by intracardial injection of pentobarbital (100 mg/kg), while under the same anesthesia.</li>
	<li>Centrifuge the sample at 350 x g for 15 min at room temperature. Transfer supernatant and store aliquots (120 &#181;L each) at -20 &#176;C until use.</li>
	<li>Immediately before in vivo implantation, thaw the above aliquot and mix 20 &#181;L with 0.5 x 106 MSCs (from either 1.9 or 3.1.2.1) detached from standard plates using trypsin/EDTA, or collect from chitosan plates by flushing (with PBS/medium).</li>
	<li>Add 6 &#181;L of 10% calcium chloride (CaCl2) to the remaining 100 &#181;L of thawed plasma in a well of 96-well plate to activate the plasma and induce formation of a clot (activated conditioned plasma: ACP).</li>
	<li>Mix cell suspension (20 &#181;L) and ACP (100 &#181;L) to form a clot (Figure 6). Place the clot within the patellar tendon defect created before closing the fascia of the stifle (see step 4.10.3).</li>
</ol>
6. Functional Outcome
<ol>
	<li>Monitor rats twice a day for signs of pain, based on the rat grimace scale (RGS)37,38 and swelling over the implantation sites. 
	NOTE: A scoring system (0&#8211;6) was developed to evaluate ambulatory function based on 3 activities, including timed hind limb standing with forelimbs supported (0-3), timed unassisted hind limb standing (0&#8211;2), and the ability to climb a 17 cm plastic cage wall (0&#8211;1) (Table 1).</li>
	<li>Evaluate rats for the two hind limb standing activities in the morning and in the evening of each time point to calculate an average score.</li>
	<li>Evaluate rats for the ability to successfully climb a 17 cm plastic cage wall with both hind limbs reaching the top.</li>
</ol>
7. Gross Appearance and Histopathology of the Patellar Tendon
<ol>
	<li>Euthanize rats at 7 days (to evaluate inflammation) or 28 days (to evaluate tissue healing) post treatment by intracardial injection of pentobarbital (100 mg/kg) under anesthesia with 8 % sevoflurane and 2 L 100% oxygen delivered via mask.</li>
	<li>Harvest patella-tendon-tibia tuberosity units by scalpel and scissors after euthanasia. Remove soft tissues and ligaments around the stifle, except for the patellar tendon.</li>
	<li>Examine each specimen for gross appearance and thickening of the tendon (Figure 7).</li>
	<li>Orient the specimen by placing a surgeon&#39;s knot of 5.0 Polydioxanone on the proximal and lateral aspect of the tendon. Fix each specimen in 10% neutral buffered formalin solution and obtain transverse sections (5 &#181;m) from the mid-portion of each tendon.</li>
	<li>Stain the sections using hematoxylin and eosin, and Masson&#39;s Trichrome staining following standard protocols.</li>
	<li>Examine section to detect the presence of hematoma within the defect, as well as pathological changes such as inflammation.</li>
	<li>Evaluate the histological score of sections using the previously published scoring system, based on collagen grade, degree of angiogenesis, and cartilage formation (Table 2)39.</li>
</ol>

The authors have no conflict of interest to disclose.

Equine cells were selected for this project because we eventually intend to test candidate approaches in the management of natural tendinopathies in horses. Indeed, tendon injuries in horses are appealing as natural models of tendinopathy in man because of the biological similarity between the equine superficial digital flexor and Achilles tendon in humans41. The cell surface markers CD44, CD90, CD105, CD34, and MHC II were selected for immunophenotyping of cells, in accordance with the criteria r...

Tendon injury is one of the most common causes of significant pain and muscle atrophy across species1. In veterinary medicine, tendon and ligament injuries are of special interest in horses, as 82% of all injuries in race horses involve the musculoskeletal system, and 46% of those affect tendons and ligaments2,3. Scar tissue formation affects the biomechanical properties of healed tendons and explains the guarded prognosis for return to athletic use after flexor tendon injuries; re-injury occurs within 2 years in up to 67% of horses treated conservatively4. Regenerative medicine provides novel alternatives to a condition that challenges traditional treatments. Autologous stem cell therapy has produced some encouraging results5,6 but is limited by the morbidity associated with tissue collection, delayed administration due to processing/reprogramming of cells, and the influence of the patient&#39;s health status (such as age) on the properties of stem cells7,8. These limitations provide a rationale for investigating allogeneic stem cells as an off-the-shelf alternative. Fetal adnexa-derived cells are appealing candidates because they circumvent the ethical concerns and risk of teratoma formation associated with embryonic stem cells. Among fetal adnexa, umbilical cord matrix (UCM), also named Wharton&#39;s Jelly, is abundant and easy to collect.
Regardless of cell source, enhancing stemness is essential to establish a cell bank for allogenic regenerative medicine. From a functional standpoint, stemness can be defined as the potential for self-renewal and multi-lineage differentiation9. Evidence of stemness relies on proliferation and differentiation assays, along with expression of gene markers Oct4, Sox2, and Nanog9. One strategy to enhance stemness relies on the use of biomaterials to serve as void fillers and carriers enhancing proliferation and differentiation of UCM-MSCs. This approach eliminates concerns regarding manipulation of transcriptional factors to reprogram mature cells into induced pluripotent cells. Among biomaterials considered as potential carriers for stem cells, chitosan is appealing for its biocompatibility and degradability10. This natural aminopolysaccharide is formed by alkaline deacetylation of chitin, the second most abundant natural polysaccharide, primarily obtained as a subproduct of shellfish10. We have previously investigated interactions between MSCs and chitosan scaffolds, and observed the formation of spheroids11,12,13,14,15,16. We also reported on the superiority of chondrogenesis on chitosan matrices12,13,14,15,16,17,18. More recently, two independent studies described spheroids formation by adipose tissue and placenta tissue derived MSCs cultured on a chitosan film19,20. This formation of spheroids not only enhanced stemness, but also improved the retention of stem cells after in vivo implantation20.
The prevalence and morbidity of tendinopathy across species have prompted the development of experimental models to study the pathophysiology of tendinopathies and test new therapies such as stem cell injections. In horses, collagenase-induced tendonitis is a common model to demonstrate efficacy using MSCs in tendon repair21. The relevance of this approach is limited, as injections cause acute inflammatory changes, whereas clinical tendinopathies usually result from chronic overstrain22,23. In addition, chemical induction of tendon disease induces a healing response and does not replicate the impaired healing process present in clinical cases22,23. Excision of a segment of the superficial digital flexor tendon has been described as a surgical model of tendonitis in horses24. More recently, a minimally invasive approach was used to restrict the traumatic damage to the central core of the superficial digital flexor tendon25. Surgical models do not simulate the fatigue mechanism that may lead to natural tendon disease, and tend to lack reproducibility in the extent of damage created25. Regardless of the model, the morbidity and cost associated with equine models of tendon diseases are additional limitations, which justify an interest in rodent models as a first step for in vivo evaluation of novel therapies.
One of the main advantages of experimental models in rodents consists of the cost and ability to control inter-individual variability. Rodents can be standardized with respect to various physiological factors due to their rapid growth rates and relatively short life spans, limiting sources of variation and therefore reducing the number of animals required to detect differences. Strategies to induce tendon diseases in rodents have relied on chemical induction, but also on surgical creation of partial tendon defects21. Surgical models may simulate natural tendinopathies better than chemical models, but can lead to higher morbidity and catastrophic failure of the damaged tendon. In that respect, rats seem better candidates than mice for these models, as their size allows creation of larger defects, thereby facilitating evaluation of tissue healing. Sprague-Dawley rats have been used in experimental studies of tendinopathies in four major tendon groups: rotator cuff, flexor, Achilles, and patellar tendons26. Among these, models involving the patellar tendon are especially appealing because of the larger size of this tendon and the ease of accessing it27. The patellar tendon attaches the quadriceps muscle to the tibial tuberosity. Within this extensor mechanism, the patella is a sesamoid bone that directs the action of the quadriceps and delineates the proximal extent of the patellar tendon. The presence of bony anchors at the proximal and distal extents of the patellar tendon facilitates biomechanical tests. Models involving the patellar tendon typically rely on unilateral surgical defects, with a contralateral intact tendon serving as a control28,29. The most common patellar tendon defect model involves excising the central portion (1 mm in width) of the patellar tendon from the distal apex of the patella to the insertion of the tibial tuberosity, while the contralateral patellar tendon is left intact. Measures of outcomes have included histology, non-destructive biomechanical testing or biomechanical testing to failure, ultrasound imaging, ex vivo fluorescence imaging, gross observation, and functional tests28,30,31. Unilateral models do not allow comparison of a proposed treatment with conservative management of a similar injury within the same animal. Similarly, comparison between several treatments requires separate animals. A bilateral model would eliminate inter-individual variations and reduce the number of animals required for a study32. However, bilateral injuries may increase morbidity, and bilateral lameness could impede treatment evaluation. A few studies briefly report the use of bilateral patellar tendon defects in rats but focus on the effects of treatments rather than peri-operative management and morbidity of the model33,34.
This study&#39;s long-term goal is to develop a strategy to improve stemness and in vivo survival of UCM-MSCs destined to allogenic transplantation. To achieve this goal, we have recently reported improved stemness of UCM-MSCs by formation of spheroids on chitosan film and incubation under hypoxic environment35. These in vitro properties were associated with improved biomechanical properties of patellar tendon defects treated with conditioned UCM-MSCs. Based on these results, the rat bilateral patellar tendon defect model seems suitable to test candidate treatments for tendon injuries36. The purpose of the study reported here is to provide detailed protocols for isolation and characterization of UCM-MSCs, preparation of a biologic delivery system for stem cells, creation and treatment of bilateral patella tendon defects, and post-operative recovery and evaluation of tissue healing within the defects.

<table><tbody><tr><td>PBS 10x</td><td>Hyclone</td><td>SH30258.01</td><td>Consumable</td></tr><tr><td>Collagenase type IA</td><td>Worthington</td><td>LS004197</td><td>Consumable</td></tr><tr><td>DMEM low glucose</td><td>Hyclone</td><td>SH30021.FS</td><td>Consumable</td></tr><tr><td>Fetal Bovine Serum</td><td>Hyclone</td><td>SH30910.03</td><td>Consumable</td></tr><tr><td>Penicillin/Streptomycin 100x</td><td>Hyclone</td><td>SV30010</td><td>Consumable</td></tr><tr><td>Trypsin 0.25%</td><td>Hyclone</td><td>SH30042.01</td><td>Consumable</td></tr><tr><td>Accutase</td><td>Innovative Cell Technologies</td><td>AT104</td><td>Consumable</td></tr><tr><td>Trypan blue</td><td>Hyclone</td><td>SV30084.01</td><td>Consumable</td></tr><tr><td>Dimethyl Sulfoxide</td><td>Sigma</td><td>D2650</td><td>Consumable</td></tr><tr><td>Chitosan</td><td>Sigma</td><td>C3646</td><td>Consumable</td></tr><tr><td>Sodium Hydroxide</td><td>Sigma</td><td>S8045</td><td>Consumable</td></tr><tr><td>Bovine Serum Albumin</td><td>Hyclone</td><td>SH30574.01</td><td>Consumable</td></tr><tr><td>Round bottom polystyrene tube</td><td>Corning</td><td>149591A</td><td>Consumable</td></tr><tr><td>Mouse anti-horse CD44 (FITC)</td><td>AbD serotec</td><td>MCA1082F</td><td>Consumable</td></tr><tr><td>Mouse anti-rat CD90 (FITC)</td><td>AbD serotec</td><td>MCA47FT</td><td>Consumable</td></tr><tr><td>Mouse anti-horse MHC-II (FITC)</td><td>AbD serotec</td><td>MCA1085F</td><td>Consumable</td></tr><tr><td>Mouse IgG1 (FITC) - Isotype Control</td><td>AbD serotec</td><td>MCA928F</td><td>Consumable</td></tr><tr><td>Mouse monoclonal [SN6] to CD105 (FITC)</td><td>abcam</td><td>ab11415</td><td>Consumable</td></tr><tr><td>Mouse IgG1 (FITC) - Isotype Control</td><td>abcam</td><td>ab91356</td><td>Consumable</td></tr><tr><td>Mouse anti-human CD34 (FITC)</td><td>BD</td><td>BDB560942</td><td>Consumable</td></tr><tr><td>Mouse IdG1 kappa (FITC)</td><td>BD</td><td>BDB555748</td><td>Consumable</td></tr><tr><td>7-AAD</td><td>BD</td><td>BDB559925</td><td>Consumable</td></tr><tr><td>BD Accuri C6 Flow Cytometer</td><td>BD</td><td></td><td>Equipment</td></tr><tr><td>Vacutainer 5 mL</td><td>Med Vet International</td><td>RED5.0</td><td>Consumable</td></tr><tr><td>Acid-citrate-dextrose</td><td>Sigma</td><td>C3821</td><td>Consumable</td></tr><tr><td>Calcium Chloride</td><td>Sigma</td><td>C5670</td><td>Consumable</td></tr><tr><td>Sevoflurane</td><td>JD Medical</td><td>60307-320-25</td><td>Consumable</td></tr><tr><td>Rats</td><td>Charles River</td><td>Strain code: 400</td><td>Experimental animal</td></tr><tr><td>Rat surgical kit</td><td>Harvard apparatus</td><td>728942</td><td>Equipment</td></tr><tr><td>Surgical Blade #15</td><td>MEDLINE</td><td>MDS15115</td><td>Consumable</td></tr><tr><td>Rat MD&#039;s Baytril (2 mg/Tablet),&lt;br/&gt; Rimadyl (2 mg/Tablet)</td><td>Bio Serv</td><td>F06801</td><td>Consumable</td></tr><tr><td>Polyglactin 910, 5-0</td><td>Ethicon</td><td>J436G</td><td>Consumable</td></tr><tr><td>Eosin alchol shandon</td><td>Thermo scientific</td><td>6766007</td><td>Consumable</td></tr><tr><td>Harris Hematoxylin</td><td>Thermo scientific</td><td>143907</td><td>Consumable</td></tr></tbody></table>

evaluation of stem cell therapies in a bilateral patellar tendon injury model in rats

Regenerative medicine provides novel alternatives to conditions that challenge traditional treatments. The prevalence and morbidity of tendinopathy across species, combined with the limited healing properties of this tissue, have prompted the search for cellular therapies and propelled the development of experimental models to study their efficacy. Umbilical cord matrix-derived mesenchymal stem cells (UCM-MSC) are appealing candidates because they are abundant, easy to collect, circumvent the ethical concerns and risk of teratoma formation, yet resemble primitive embryonic stem cells more closely than adult tissue-derived MSCs. Significant interest has focused on chitosan as a strategy to enhance the properties of MSCs through spheroid formation. This paper details techniques to isolate UCM-MSCs, prepare spheroids on chitosan film, and analyze the effect of spheroid formation on surface marker expression. Consequently, creation of a bilateral patellar tendon injury model in rats is described for in vivo implantation of UCM-MSC spheroids formed on chitosan film. No complication was observed in the study with respect to morbidity, stress rising effects, or tissue infection. The total functional score of the operated rats at 7 days was lower than that of normal rats, but returned to normal within 28 days after surgery. Histological scores of tissue-healing confirmed the presence of a clot in treated defects evaluated at 7 days, absence of foreign body reaction, and progressing healing at 28 days. This bilateral patella tendon defect model controls inter-individual variation via creation of an internal control in each rat, was associated with acceptable morbidity, and allowed detection of differences between untreated tendons and treatments.

In the current study, results are presented as mean &#177; SD (standard deviation). Cells were isolated from the umbilical cords of 6 mares, and percentage of isolated cell lines expressing each cell surface marker under standard or chitosan conditioning were compared with a Friedman test, as a non-parametric analysis of variance with repeated measures. For tendon defect model creation, 8 rats were used for 7 days post-surgery assessment and 12 rats were used for 28 days assessment. Resul...

Watch this Scientific Journal Video about Evaluation of Stem Cell Therapies in a Bilateral Patellar Tendon Injury Model in Rats at JoVE.com

Evaluation of Stem Cell Therapies in a Bilateral Patellar Tendon Injury Model in Rats

This paper describes the preparation and evaluation of umbilical cord matrix-derived mesenchymal stem cells spheroids with a bilateral patellar tendon defect model in a rat. This model was associated with an acceptable morbidity and was found to detect differences between untreated and treated tendons, and between the two treatments tested.

Regenerative medicine provides novel alternatives to conditions that challenge traditional treatments. The prevalence and morbidity of tendinopathy across ...

evaluation-stem-cell-therapies-bilateral-patellar-tendon-injury-model

Research

JoVE Journal

Medicine

11.1K Views.  Western University of Health Sciences. This paper describes the preparation and evaluation of umbilical cord matrix-derived mesenchymal stem cells spheroids with a bilateral patellar tendon defect model in a rat. This model was associated with an acceptable morbidity and was found to detect differences between untreated and treated tendons, and between the two treatments tested.

Video: Evaluation of Stem Cell Therapies in a Bilateral Patellar Tendon Injury Model in Rats

Treatment of Osteochondral Defects in the Rabbit's Knee Joint by Implantation of Allogeneic Mesenchymal Stem Cells in Fibrin Clots

The treatment of osteochondral articular defects has been challenging physicians for many years. The better understanding of interactions of articular cartilage and subchondral bone in recent years led to increased attention to restoration of the entire osteochondral unit. In comparison to chondral lesions the regeneration of osteochondral defects is much more complex and a far greater surgical and therapeutic challenge. The damaged tissue does not only include the superficial cartilage layer but also the subchondral bone. For deep, osteochondral damage, as it occurs for example with osteochondrosis dissecans, the full thickness of the defect needs to be replaced to restore the joint surface 1. Eligible therapeutic procedures have to consider these two different tissues with their different intrinsic healing potential 2. In the last decades, several surgical treatment options have emerged and have already been clinically established 3-6.
Autologous or allogeneic osteochondral transplants consist of articular cartilage and subchondral bone and allow the replacement of the entire osteochondral unit. The defects are filled with cylindrical osteochondral grafts that aim to provide a congruent hyaline cartilage covered surface 3,7,8. Disadvantages are the limited amount of available grafts, donor site morbidity (for autologous transplants) and the incongruence of the surface; thereby the application of this method is especially limited for large defects.
New approaches in the field of tissue engineering opened up promising possibilities for regenerative osteochondral therapy. The implantation of autologous chondrocytes marked the first cell based biological approach for the treatment of full-thickness cartilage lesions and is now worldwide established with good clinical results even 10 to 20 years after implantation 9,10. However, to date, this technique is not suitable for the treatment of all types of lesions such as deep defects involving the subchondral bone 11.
The sandwich-technique combines bone grafting with current approaches in Tissue Engineering 5,6. This combination seems to be able to overcome the limitations seen in osteochondral grafts alone. After autologous bone grafting to the subchondral defect area, a membrane seeded with autologous chondrocytes is sutured above and facilitates to match the topology of the graft with the injured site. Of course, the previous bone reconstruction needs additional surgical time and often even an additional surgery. Moreover, to date, long-term data is missing 12.
Tissue Engineering without additional bone grafting aims to restore the complex structure and properties of native articular cartilage by chondrogenic and osteogenic potential of the transplanted cells. However, again, it is usually only the cartilage tissue that is more or less regenerated. Additional osteochondral damage needs a specific further treatment. In order to achieve a regeneration of the multilayered structure of osteochondral defects, three-dimensional tissue engineered products seeded with autologous/allogeneic cells might provide a good regeneration capacity 11.
Beside autologous chondrocytes, mesenchymal stem cells (MSC) seem to be an attractive alternative for the development of a full-thickness cartilage tissue. In numerous preclinical in vitro and in vivo studies, mesenchymal stem cells have displayed excellent tissue regeneration potential 13,14. The important advantage of mesenchymal stem cells especially for the treatment of osteochondral defects is that they have the capacity to differentiate in osteocytes as well as chondrocytes. Therefore, they potentially allow a multilayered regeneration of the defect.
In recent years, several scaffolds with osteochondral regenerative potential have therefore been developed and evaluated with promising preliminary results 1,15-18. Furthermore, fibrin glue as a cell carrier became one of the preferred techniques in experimental cartilage repair and has already successfully been used in several animal studies 19-21 and even first human trials 22.
The following protocol will demonstrate an experimental technique for isolating mesenchymal stem cells from a rabbit's bone marrow, for subsequent proliferation in cell culture and for preparing a standardized in vitro-model for fibrin-cell-clots. Finally, a technique for the implantation of pre-established fibrin-cell-clots into artificial osteochondral defects of the rabbit's knee joint will be described.

An experimental technique for the treatment of osteochondral defects in the rabbit's knee joint is described. The implantation of allogeneic mesenchymal stem cells into osteochondral defects provides a promising development in the field of tissue engineering. The preparation of fibrin-cell-clots in vitro offers a standardized method for implantation.

The treatment of osteochondral articular defects has been challenging physicians for many years. The better understanding of interactions of articular ...

Athymic Rat Model for Evaluation of Engineered Anterior Cruciate Ligament Grafts

Anterior cruciate ligament (ACL) rupture is a common ligamentous injury that often requires surgery because the ACL does not heal well without intervention. Current treatment strategies include ligament reconstruction with either autograft or allograft, which each have their associated limitations. Thus, there is interest in designing a tissue-engineered graft for use in ACL reconstruction. We describe the fabrication of an electrospun polymer graft for use in ACL tissue engineering. This polycaprolactone graft is biocompatible, biodegradable, porous, and is comprised of aligned fibers. Because an animal model is necessary to evaluate such a graft, this paper describes an intra-articular athymic rat model of ACL reconstruction that can be used to evaluate engineered grafts, including those seeded with xenogeneic cells. Representative histology and biomechanical testing results at 16 weeks postoperatively are presented, with grafts tested immediately post-implantation and contralateral native ACLs serving as controls. The present study provides a reproducible animal model with which to evaluate tissue engineered ACL grafts, and demonstrates the potential of a regenerative medicine approach to treatment of ACL rupture.

Animal models are important tools for the evaluation of tissue-engineered grafts. This paper presents the protocol for preparing an electrospun biodegradable polymer graft for use in anterior cruciate ligament tissue engineering, as well as a surgical protocol for implantation in a rat model.

Anterior cruciate ligament (ACL) rupture is a common ligamentous injury that often requires surgery because the ACL does not heal well without ...

Bioengineering

Applications of In Vivo Functional Testing of the Rat Tibialis Anterior for Evaluating Tissue Engineered Skeletal Muscle Repair

Despite the regenerative capacity of skeletal muscle, permanent functional and/or cosmetic deficits (e.g., volumetric muscle loss (VML) resulting from traumatic injury, disease and various congenital, genetic and acquired conditions are quite common. Tissue engineering and regenerative medicine technologies have enormous potential to provide a therapeutic solution. However, utilization of biologically relevant animal models in combination with longitudinal assessments of pertinent functional measures are critical to the development of improved regenerative therapeutics for treatment of VML-like injuries. In that regard, a commercial muscle lever system can be used to measure length, tension, force and velocity parameters in skeletal muscle. We used this system, in conjunction with a high power, bi-phase stimulator, to measure in vivo force production in response to activation of the anterior crural compartment of the rat hindlimb. We have previously used this equipment to assess the functional impact of VML injury on the tibialis anterior (TA) muscle, as well as the extent of functional recovery following treatment of the injured TA muscle with our tissue engineered muscle repair (TEMR) technology. For such studies, the left foot of an anaesthetized rat is securely anchored to a footplate linked to a servomotor, and the common peroneal nerve is stimulated by two percutaneous needle electrodes to elicit muscle contraction and dorsiflexion of the foot. The peroneal nerve stimulation-induced muscle contraction is measured over a range of stimulation frequencies (1-200 Hz), to ensure an eventual plateau in force production that allows for an accurate determination of peak tetanic force. In addition to evaluation of the extent of VML injury as well as the degree of functional recovery following treatment, this methodology can be easily applied to study diverse aspects of muscle physiology and pathophysiology. Such an approach should assist with the more rational development of improved therapeutics for muscle repair and regeneration.

Applications of In Vivo Functional Testing of the Rat Tibialis Anterior for Evaluating Tissue Engineered Skeletal Muscle Repair

We describe an in vivo protocol to measure dorsiflexion of the foot following stimulation of the peroneal nerve and contraction of the anterior crural compartment of the rat hindlimb. Such measurements are an indispensable translational tool for evaluating skeletal muscle pathology and tissue engineering approaches to muscle repair and regeneration.

Despite the regenerative capacity of skeletal muscle, permanent functional and/or cosmetic deficits (e.g., volumetric muscle loss (VML) resulting from ...

In Vivo Imaging and Tracking of Technetium-99m Labeled Bone Marrow Mesenchymal Stem Cells in Equine Tendinopathy

Recent advances in the application of bone marrow mesenchymal stem cells (BMMSC) for the treatment of tendon and ligament injuries in the horse suggest improved outcome measures in both experimental and clinical studies. Although the BMMSC are implanted into the tendon lesion in large numbers (usually 10 - 20 million cells), only a relatively small number survive (&#60;10%) although these can persist for up to 5 months after implantation. This appears to be a common observation in other species where BMMSC have been implanted into other tissues and it is important to understand when this loss occurs, how many survive the initial implantation process and whether the cells are cleared into other organs. Tracking the fate of the cells can be achieved by radiolabeling the BMMSC prior to implantation which allows non-invasive in vivo imaging of cell location and quantification of cell numbers.
This protocol describes a cell labeling procedure that uses Technetium-99m (Tc-99m), and tracking of these cells following implantation into injured flexor tendons in horses. Tc-99m is a short-lived (t1/2 of 6.01 hr) isotope that emits gamma rays and can be internalized by cells in the presence of the lipophilic compound hexamethylpropyleneamine oxime (HMPAO). These properties make it ideal for use in nuclear medicine clinics for the diagnosis of many different diseases. The fate of the labeled cells can be followed in the short term (up to 36 hr) by gamma scintigraphy to quantify both the number of cells retained in the lesion and distribution of the cells into lungs, thyroid and other organs. This technique is adapted from the labeling of blood leukocytes and could be utilized to image implanted BMMSC in other organs.

In Vivo Imaging and Tracking of Technetium-99m Labeled Bone Marrow Mesenchymal Stem Cells in Equine Tendinopathy

This protocol describes the radiolabeling of equine mesenchymal stem cells and their implantation into tendon injuries in the horse in order to determine cell survival and tissue distribution using gamma scintigraphy.

Recent advances in the application of bone marrow mesenchymal stem cells (BMMSC) for the treatment of tendon and ligament injuries in the horse suggest ...

A Rat Tibial Growth Plate Injury Model to Characterize Repair Mechanisms and Evaluate Growth Plate Regeneration Strategies

A third of all pediatric fractures involve the growth plate and can result in impaired bone growth. The growth plate (or physis) is cartilage tissue found at the end of all long bones in children that is responsible for longitudinal bone growth. Once damaged, cartilage tissue within the growth plate can undergo premature ossification and lead to unwanted bony repair tissue, which forms a "bony bar." In some cases, this bony bar can result in bone growth deformities, such as angular deformities, or it can completely halt longitudinal bone growth. There is currently no clinical treatment that can fully repair an injured growth plate. Using an animal model of growth plate injury to better understand the mechanisms underlying bony bar formation and to identify ways to inhibit it is a great opportunity to develop better treatments for growth plate injuries. This protocol describes how to disrupt the rat proximal tibial growth plate using a drill-hole defect. This small animal model reliably produces a bony bar and can result in growth deformities similar to those seen in children. This model allows for investigation into the molecular mechanisms of bony bar formation and serves as a means to test potential treatment options for growth plate injuries.

The growth plate is a cartilaginous region in children's long bones where longitudinal growth occurs. When injured, bony tissue can form and impair growth. We describe a rat model of growth plate injury that leads to bony repair tissue, allowing the study of repair mechanisms and growth plate regeneration strategies.

A third of all pediatric fractures involve the growth plate and can result in impaired bone growth. The growth plate (or physis) is cartilage tissue found ...

Effects of Allogeneic Platelet-Rich Plasma (PRP) on the Healing Process of Sectioned Achilles Tendons of Rats: A Methodological Description

This article describes the experimental procedures used to observe if PRP can positively affect tendon healing. There are 4 main steps to follow: induce a lesion in the Achilles tendon; prepare PRP and inject it (or the saline solution); remove the tendon; and perform biomechanical, molecular, and histological evaluations. At each step, all the procedures and methods are described in detail, so they can be reproduced easily.
Achilles tendons have been surgically sectioned (removal of a 5-mm long section). Afterwards, PRP or saline solution was injected to study whether PRP has a positive effect on the healing of the tendon. Three groups of 40 animals (a total of 120 rats were used in this study) were subdivided into 2 subgroups: PRP injection group and a saline injection control group. Rats were sacrificed at increasing time points (Group A: 5 days; Group B: 15 days; Group C: 30 days) and tendons were removed. 90 tendons underwent biomechanical testing before performing transcriptomic analysis and the 30 remaining tendons were submitted to histological analysis.

Effects of Allogeneic Platelet-Rich Plasma PRP on the Healing Process of Sectioned Achilles Tendons of Rats: A Methodological Description

This protocol describes the evaluation process of healing tendons in rats that have been injected with allogeneic platelet rich plasma (PRP) or saline solution after removing part of the Achilles tendon. The progress of tendon healing is evaluated at several time points using different types of analyses.

This article describes the experimental procedures used to observe if PRP can positively affect tendon healing. There are 4 main steps to follow: induce a ...

Understanding Tendon Impingement &#8211; Murine Explant Model for Studying Mechanobiology

Murine Hind Limb Explant Model for Studying the Mechanobiology of Achilles Tendon Impingement

Tendon impingement upon bone generates a multiaxial mechanical strain environment with markedly elevated transverse compressive strain, which elicits a localized fibrocartilage phenotype characterized by accumulation of glycosaminoglycan (GAG)-rich matrix and remodeling of the collagen network. While fibrocartilage is a normal feature in impinged regions of healthy tendons, excess GAG deposition and disorganization of the collagen network are hallmark features of tendinopathy. Accordingly, impingement is clinically recognized as an important extrinsic factor in the initiation and progression of tendinopathy. Nevertheless, the mechanobiology underlying tendon impingement remains understudied. Prior efforts to elucidate the cellular response to tendon impingement have applied uniaxial compression to cells and excised tendon explants in vitro. However, isolated cells lack a three-dimensional extracellular environment crucial to mechanoresponse, and both in vitro and excised explant studies fail to recapitulate the multiaxial strain environment generated by tendon impingement in vivo, which depends on anatomical features of the impinged region. Moreover, in vivo models of tendon impingement lack control over the mechanical strain environment. To overcome these limitations, we present a novel murine hind limb explant model suitable for studying the mechanobiology of Achilles tendon impingement. This model maintains the Achilles tendon in situ to preserve local anatomy and reproduces the multiaxial strain environment generated by impingement of the Achilles tendon insertion upon the calcaneus during passively applied ankle dorsiflexion while retaining cells within their native environment. We describe a tissue culture protocol integral to this model and present data establishing sustained explant viability over 7 days. The representative results demonstrate enhanced histological GAG staining and decreased collagen fiber alignment secondary to impingement, suggesting elevated fibrocartilage formation. This model can easily be adapted to investigate different mechanical loading regimens and allows for the manipulation of molecular pathways of interest to identify mechanisms mediating phenotypic change in the Achilles tendon in response to impingement.

Author Spotlight: Unraveling the Mechanobiology of Tendon Impingement &#8211; A Multiaxial Murine Hind Limb Explant Model 

We present a custom experimental platform and tissue culture protocol that recreates fibrocartilaginous change driven by impingement of the Achilles tendon insertion in murine hind limb explants with sustained cell viability, providing a model suitable for exploring the mechanobiology of tendon impingement.

Tendon impingement upon bone generates a multiaxial mechanical strain environment with markedly elevated transverse compressive strain, which elicits a ...

Applying a Three-dimensional Uniaxial Mechanical Stimulation Bioreactor System to Induce Tenogenic Differentiation of Tendon-Derived Stem Cells

Tendinopathy is a common chronic tendon disease relating to inflammation and degeneration in an orthopaedic area. With high morbidity, limited self-repairing capacity and, most importantly, no definitive treatments, tendinopathy still influences patients&#8217; life quality negatively. Tendon-derived stem cells (TDSCs), as primary precursor cells of tendon cells, play an essential role in both the development of tendinopathy, and functional and structural restoration after tendinopathy. Thus, a method that can in vitro mimic the in vivo differentiation of TDSCs into tendon cells would be useful. Here, the present protocol describes a method based on a three-dimensional (3D) uniaxial stretching system to stimulate the TDSCs to differentiate into tendon-like tissues. There are seven stages of the present protocol: isolation of mice TDSCs, culture and expansion of mice TDSCs, preparation of stimulation culture medium for cell sheet formation, cell sheet formation by culturing in stimulation medium, preparation of 3D tendon stem cell construct, assembly of the uniaxial-stretching mechanical stimulation complex, and evaluation of the mechanical stimulated in vitro tendon-like tissue. The effectiveness was demonstrated by histology. The entire procedure takes less than 3 weeks. To promote extracellular matrix deposition, 4.4 mg/mL ascorbic acid was used in the stimulation culture medium. A separated chamber with a linear motor provides accurate mechanical loading and is portable and easily adjusted, which is applied for the bioreactor. The loading regime in the present protocol was 6% strain, 0.25 Hz, 8 h, followed by 16 h rest for 6 days. This protocol could mimic cell differentiation in the tendon, which is helpful for the investigation of the pathological process of tendinopathy. Moreover, the tendon-like tissue is potentially used to promote tendon healing in tendon injury as an engineered autologous graft. To sum up, the present protocol is simple, economic, reproducible and valid.

A three-dimensional uniaxial mechanical stimulation bioreactor system is an ideal bioreactor for tenogenic-specific differentiation of tendon-derived stem cells and neo-tendon formation.

Tendinopathy is a common chronic tendon disease relating to inflammation and degeneration in an orthopaedic area. With high morbidity, limited ...

Development and Evaluation of a Rat Model of Full-Thickness Cartilage Defects

Cartilage defects of the knee joint caused by trauma are a common sports joint injury in the clinic, and these defects result in joint pain, impaired movement, and eventually, knee osteoarthritis (kOA). However, there is little effective treatment for cartilage defects or even kOA. Animal models are important for developing therapeutic drugs, but the existing models for cartilage defects are unsatisfactory. This work established a full-thickness cartilage defects (FTCD) model by drilling holes in the femoral trochlear groove of rats, and the subsequent pain behavior and histopathological changes were used as readout experiments. After surgery, the mechanical withdrawal threshold was decreased, chondrocytes at the injured site were lost, matrix metalloproteinase MMP13 expression was increased, and type II collagen expression decreased, consistent with the pathological changes observed in human cartilage defects. This methodology is easy and simple to perform and enables gross observation immediately after the injury. Furthermore, this model can successfully mimic clinical cartilage defects, thus providing a platform for studying the pathological process of cartilage defects and developing corresponding therapeutic drugs.

This protocol establishes a full-thickness cartilage defects (FTCD) model by drilling holes in the femoral trochlear groove of rats and measuring the subsequent pain behavior and histopathological changes.

Cartilage defects of the knee joint caused by trauma are a common sports joint injury in the clinic, and these defects result in joint pain, impaired ...

Development of a Rabbit Chronic-Like Rotator Cuff Injury Model for Study of Fibrosis and Muscular Fatty Degeneration

Rabbit rotator cuff (RC) pathophysiology can lead to progressive and highly degenerative changes in its associated musculature and tendons, which negatively influences clinically relevant parameters, such as strength and retraction of the muscle-tendon/myotendinous unit, ultimately causing loss of shoulder function and negatively affecting RC repair outcomes. Animal models that mimic aspects of human RC anatomy and pathophysiology are crucial for advancing the conceptual understanding of injury progression and developing effective tissue engineering and regenerative medicine-based therapeutics.
Within this context, a rabbit subscapularis (SSC) model is suitable due to (i) its anatomical similarity to the human supraspinatus (SSP) bone-tendon-muscle unit, which is the most frequently injured RC site; (ii) its pathophysiological similarity to humans in terms of fibrosis and muscle fatty degeneration (FD); and (iii) its amenability to surgical procedures. Therefore, the goal of this study is to describe the surgical techniques for inducing SSC RC injury. Briefly, the procedure involves the isolation of the SSC by identifying the coracobrachialis muscle followed by a full-thickness transection at the muscle-tendon junction and wrapping the free end of the muscle-tendon junction with a silicone-based penrose tubing to prevent spontaneous reattachment. Histologic evaluations are performed to monitor the progression of muscle FD at 4 weeks post-surgery using hematoxylin and eosin (H&#38;E) as well as Masson&#39;s trichrome staining.
Loss of muscle and FD were evident 4 weeks after transection of the SSC muscle-tendon junction, similar to human RC pathophysiological conditions. This protocol demonstrates the steps for successfully establishing a chronic-like rabbit SSC RC injury model, which can serve as a powerful tool to study skeletal muscle changes associated with RC pathophysiology and aid the development of novel therapeutic strategies for chronic-like RC tears.

This study details procedures for establishing a chronic-like rabbit rotator cuff (RC) injury. Specifically, the injury is created in the subscapularis (SSC) muscle-tendon/myotendinous unit to mimic human RC anatomy and pathophysiology, including severe muscle fatty degeneration (FD). This protocol can be applied to study RC injuries and assess regenerative therapies.

Evaluation of Stem Cell Therapies in a Bilateral Patellar Tendon Injury Model in Rats

Summary

Explore More Videos

Chapters in this video

Treatment of Osteochondral Defects in the Rabbit's Knee Joint by Implantation of Allogeneic Mesenchymal Stem Cells in Fibrin Clots

Athymic Rat Model for Evaluation of Engineered Anterior Cruciate Ligament Grafts

Applications of In Vivo Functional Testing of the Rat Tibialis Anterior for Evaluating Tissue Engineered Skeletal Muscle Repair

In Vivo Imaging and Tracking of Technetium-99m Labeled Bone Marrow Mesenchymal Stem Cells in Equine Tendinopathy

A Rat Tibial Growth Plate Injury Model to Characterize Repair Mechanisms and Evaluate Growth Plate Regeneration Strategies

Effects of Allogeneic Platelet-Rich Plasma (PRP) on the Healing Process of Sectioned Achilles Tendons of Rats: A Methodological Description

Murine Hind Limb Explant Model for Studying the Mechanobiology of Achilles Tendon Impingement

Applying a Three-dimensional Uniaxial Mechanical Stimulation Bioreactor System to Induce Tenogenic Differentiation of Tendon-Derived Stem Cells

Development and Evaluation of a Rat Model of Full-Thickness Cartilage Defects

Development of a Rabbit Chronic-Like Rotator Cuff Injury Model for Study of Fibrosis and Muscular Fatty Degeneration